The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C), and paricalcitol (P)neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Corcept Therapeutics; Genzyme (I); InVitae; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genentech (I); Genzyme (I); Ipsen; Novartis (I); Teva (I)
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Gayle S. Jameson
No Relationships to Disclose
 
Courtney Edwards Snyder
No Relationships to Disclose
 
Frank Yung-Chin Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Tempus
Patents, Royalties, Other Intellectual Property - Clinical trial software.
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; Imaging Endpoints; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma
Research Funding - AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BiolineRx (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); TTC Oncology (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Sunil Sharma
Stock and Other Ownership Interests - Bauerfeind; Beta Cat Pharmaceuticals; ConverGene; Elevar Therapeutics; HLB; Proteus Digital Health; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma; Bauerfeind; Dracen; Exelixis; Exelixis; Hengrui Therapeutics; Loxo; Tarveda Therapeutics
Consulting or Advisory Role - Bauerfeind; Dracen
Research Funding - AADi; Celgene; City of Hope; City of Hope; Hengrui Therapeutics; Honor Health; Honor Health; Inhibrx; Merck; Novartis; OncoMed; Plexxikon; Syndax; Tesaro; Toray Industries
Patents, Royalties, Other Intellectual Property - International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
Travel, Accommodations, Expenses - Bauerfeind; Dracen; Exelixis; Hengrui Therapeutics; Loxo; Tarveda Therapeutics
 
Carol Guarnieri
No Relationships to Disclose
 
Amar Thosani
No Relationships to Disclose
 
Syed Rahmanuddin
No Relationships to Disclose
 
Ronald Lee Korn
Employment - Imaging Endpoints
Stock and Other Ownership Interests - Globavir; Teladoc
Consulting or Advisory Role - Dracen; ImaginAB
Research Funding - Tyme
Patents, Royalties, Other Intellectual Property - Determination of Breast Cancer Malignancy using Textural analysis
Travel, Accommodations, Expenses - Deciphera; ImaginAb; Kite/Gilead
 
Steven Sckolnik
No Relationships to Disclose
 
Sharon Salontai
No Relationships to Disclose
 
Rachel Wyman
No Relationships to Disclose
 
Susan Haag
No Relationships to Disclose
 
Kevin Gosselin
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; CerRx; Medtronic; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - 2X Oncology; 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Adicet Bio; Aeglea Biotherapeutics; Agenus; AiMed; Alpha Cancer Technologies; Amunix; Apeiron Biologics; Aptose Biosciences; Array BioPharma; Arvinas; Athenex; Axis Therapeutics; Bellicum Pharmaceuticals; BiolineRx; BioXCel therapeutics; Boston Scientific; Bryologyx; CanBas; Cancer Prevention Pharmaceuticals; Celgene; Codiak Biosciences; Corcept Therapeutics; CV6 Therapeutics; CytomX Therapeutics; Decoy Biosystems; DNAtrix; DrugCendR; EMD Serono; Erimos Pharmaceuticals; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; Five Prime Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; GiraFpharma; Globe Life Science; Helix BioPharma; Horizon Discovery; HUYA Bioscience International; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; Intezyne Technologies; Ipsen; Jounce Therapeutics; Kalos Therapeutics; Kelun; Kura Oncology; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; MaveriX Oncology; Medical Prognosis Institute; Northern Biologics; Novita Pharmaceuticals; Novocure; Nucana; Oncology Venture; Oncolyze; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; RadImmune; Reflexion Medical; RenovoRx; Samumed; Samus Therapeutics; Senhwa Biosciences; Sirnaomics; SOBI; SOTIO; Strategia Therapeutics; Sun Biopharma; Synergene; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trovagene; Varian Biopharma; Verily; Vicus Therapeutics; Viracta Therapeutics; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Albert Amini
No Relationships to Disclose